我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
+ Author Affiliations

, Q3 g' [6 Y+ Y1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
, I& U, w! x' J3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& g* G& h  [+ G" B6 W4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 `: b# _& ~9 h# I$ ]- x7Kinki University School of Medicine, Osaka 589-8511, Japan
8Izumi Municipal Hospital, Osaka 594-0071, Japan
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
6 j* n& ^, l: [+ ^+ s4 wCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.

2 U5 n1 R6 L7 F: ]& C* N

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
6 l, D, T; m; |7 D; O4 o! t3 j1 f
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

; q, P; \0 r# n2 a( ]0 C  sAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

Published online on: Thursday, December 1, 2011

Doi: 10.3892/ol.2011.507
5 ?% @4 N, I; C) r7 B
; k: l  h% I6 C$ `8 \' d: f4 qPages: 405-410

) \6 z5 w0 _2 Q* t9 qAbstract:
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.

9 e& y2 x0 {5 L8 X- [

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
1 h4 _" `" Y) b5 h9 _! wF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
, }- r) p) m! G, j+ Author Affiliations
+ G3 [" K" r. G- h2 D' d! X1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2Department of Thoracic Surgery, Kyoto University, Kyoto
. \' c2 A; B6 P, ]4 m9 s3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
$ ]' Y5 u: m) X; l- J2 ^) s$ y6 L&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
! e/ v) r! [- Z/ T- \Revision received November 11, 2010.
# P- n, p( u8 O* C7 Q1 k! n, [Accepted November 17, 2010.
; i8 v; K' R) ~& H4 tAbstract
2 j; i' m1 ?$ e2 D2 s; |9 l& i# o& dBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
9 O0 e- \% h% w- pResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
  S) B8 Z" {' e% x% T$ OConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
! ]9 y4 p: G5 ?' _+ A, {

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
. q/ q9 R% r* J) h4 `# m今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？
1 i& g2 [/ s9 q" ^" a2 {7 s

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
* ?+ U  A5 b- rhttp://clinicaltrials.gov/ct2/show/NCT01523587
# w) A" j* j# f
" `; v8 D9 z6 V* B- QBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
http://clinicaltrials.gov/ct2/show/NCT01156545

8 }# A: y  ^0 L
  q$ [* F+ |6 ?* T$ m+ q* t从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
: m8 _, c0 `8 o; K0 S7 n至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

1 l0 S8 {; J. S- r9 ]3 C                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
/ {; e. W/ p& C) F至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
+ F4 h3 h1 w& A  y1 Z- h4 I不错。